ECSP24004256A - Composiciones que contienen adenosín trifosfato (atp) y métodos de uso para la función cognitiva - Google Patents
Composiciones que contienen adenosín trifosfato (atp) y métodos de uso para la función cognitivaInfo
- Publication number
- ECSP24004256A ECSP24004256A ECSENADI20244256A ECDI202404256A ECSP24004256A EC SP24004256 A ECSP24004256 A EC SP24004256A EC SENADI20244256 A ECSENADI20244256 A EC SENADI20244256A EC DI202404256 A ECDI202404256 A EC DI202404256A EC SP24004256 A ECSP24004256 A EC SP24004256A
- Authority
- EC
- Ecuador
- Prior art keywords
- atp
- methods
- cognitive function
- compositions containing
- adenosine triphosphate
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 230000003920 cognitive function Effects 0.000 title abstract 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 title 2
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 title 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 abstract 2
- 229960001456 adenosine triphosphate Drugs 0.000 abstract 2
- 230000036997 mental performance Effects 0.000 abstract 1
- 230000036651 mood Effects 0.000 abstract 1
- 230000002232 neuromuscular Effects 0.000 abstract 1
- 230000035484 reaction time Effects 0.000 abstract 1
- 230000009257 reactivity Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Se proporcionan métodos de uso y composiciones que comprenden una fuente de adenosín 5-trifosfato (ATP). La administración de las composiciones descritas mejora la función cognitiva, los tiempos de reacción, la concentración, el estado de ánimo, la reactividad neuromuscular y/u optimiza el rendimiento mental.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163213378P | 2021-06-22 | 2021-06-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP24004256A true ECSP24004256A (es) | 2024-02-29 |
Family
ID=84544774
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI20244256A ECSP24004256A (es) | 2021-06-22 | 2024-01-19 | Composiciones que contienen adenosín trifosfato (atp) y métodos de uso para la función cognitiva |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP4358972A1 (es) |
| JP (1) | JP2024524288A (es) |
| CN (1) | CN117835985A (es) |
| AU (1) | AU2022297444A1 (es) |
| CA (1) | CA3224861A1 (es) |
| CO (1) | CO2024000517A2 (es) |
| EC (1) | ECSP24004256A (es) |
| WO (1) | WO2022271813A1 (es) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7629329B2 (en) * | 2001-06-04 | 2009-12-08 | Tsi Health Sciences, Inc. | Method for increasing muscle mass and strength through administration of adenosine triphosphate |
| MX354875B (es) * | 2010-12-23 | 2018-03-22 | Amazentis Sa | Composiciones y métodos para mejorar la función mitocondrial y tratar enfermedades neurodegenerativas y trastornos cognitivos. |
| CN104902912A (zh) * | 2013-01-03 | 2015-09-09 | 莱拉营养食品有限公司 | 用于增进身体活动能力和能量水平的协同膳食补充剂组合物 |
-
2022
- 2022-06-22 CN CN202280056829.6A patent/CN117835985A/zh active Pending
- 2022-06-22 JP JP2023579443A patent/JP2024524288A/ja active Pending
- 2022-06-22 EP EP22829221.5A patent/EP4358972A1/en active Pending
- 2022-06-22 CA CA3224861A patent/CA3224861A1/en active Pending
- 2022-06-22 AU AU2022297444A patent/AU2022297444A1/en active Pending
- 2022-06-22 WO PCT/US2022/034510 patent/WO2022271813A1/en active Application Filing
-
2024
- 2024-01-19 EC ECSENADI20244256A patent/ECSP24004256A/es unknown
- 2024-01-22 CO CONC2024/0000517A patent/CO2024000517A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4358972A1 (en) | 2024-05-01 |
| AU2022297444A1 (en) | 2024-01-18 |
| CN117835985A (zh) | 2024-04-05 |
| CO2024000517A2 (es) | 2024-05-10 |
| WO2022271813A1 (en) | 2022-12-29 |
| CA3224861A1 (en) | 2022-12-29 |
| JP2024524288A (ja) | 2024-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR8402A (es) | Indazol-o-glucosidos sustitutos | |
| GT201000061A (es) | Derivados de uracilo o timina para el tratamiento de hepatitis c | |
| PA8608901A1 (es) | Derivados de piperazina | |
| UY37952A (es) | Formulaciones de un inhibidor de la quinasa trk macrocíclica | |
| CO2022001210A2 (es) | Conjugados de il-2 y métodos de uso para tratar enfermedades autoinmunes | |
| UY28679A1 (es) | Nuevos derivados organofosforados de los indazoles y utilización como médicamentos. | |
| CL2022001743A1 (es) | Dosis de gamma-hidroxibutirato (ghb) | |
| CL2021001753A1 (es) | Compuestos derivados de 2,4-diaminoquinazolina; composición farmacéutica; y su uso para el tratamiento de una infección vírica, cáncer, entre otras (divisional de solicitud 202002253). | |
| PE20220017A1 (es) | Inhibidores del kcnt1 y metodos de uso | |
| PE20051161A1 (es) | Metodos para tratar la infeccion por vih | |
| CU20200008A7 (es) | Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas, métodos para preparar dichos compuestos y composiciones farmacéuticas que los contienen | |
| UY27894A1 (es) | Derivados de cinamida. | |
| AR062425A1 (es) | Formulacion de aerosol para la inhalacion de agonistas beta | |
| CO2023014622A2 (es) | Conjugados de anticuerpo-fármaco anti-c-met | |
| CO2022008662A2 (es) | Degradadores de smarca y usos de los mismos | |
| CO2023014770A2 (es) | Degradadores de cdk2 y sus usos | |
| CO2022013414A2 (es) | Degradadores de mdm2 y usos de los mismos | |
| CO2018011231A2 (es) | Derivados de [1,2,3]triazolo[4,5-d]pirimidina con afinidad por los receptores canabinoides tipo-2 | |
| CO2022008817A2 (es) | Macrociclos para uso en el tratamiento de enfermedades | |
| CO2024001102A2 (es) | Compuestos de pirazolopiridinona | |
| BRPI0814725B8 (pt) | uso da composição antiviral | |
| ECSP24004256A (es) | Composiciones que contienen adenosín trifosfato (atp) y métodos de uso para la función cognitiva | |
| UY38759A (es) | Tienilhidroxiisoxazolinas y derivados de las mismas | |
| CL2009000599A1 (es) | Compuestos derivados de 4,5-dihidro-1h-pirazol(4,3-g)benzotiazol sustituidos; composicion farmaceutica; utiles para el tratamiento y prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunes, entre otras. | |
| BR112023015715A2 (pt) | Inibidor de cdk |